Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
| Autor: | Amod, A, Buse, JB, McGuire, DK, Pieber, TR, Pop-Busui, R, Pratley, RE, Zinman, B, Hansen, MB, Jia, T, Mark, T, Poulter, NR, DEVOTE Study Group |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Insulin degludec
CHRONIC KIDNEY-DISEASE medicine.medical_specialty ALBUMINURIA Endocrinology Diabetes and Metabolism medicine.medical_treatment DEVOTE Study Group Renal function 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology ALL-CAUSE urologic and male genital diseases 03 medical and health sciences Endocrinology & Metabolism MELLITUS DEGLUDEC 0302 clinical medicine Insulin glargine U100 Diabetes mellitus Internal medicine Chronic kidney disease Internal Medicine Medicine Original Research Severe hypoglycemia Science & Technology business.industry Insulin glargine Insulin EMPAGLIFLOZIN medicine.disease Cardiovascular disease female genital diseases and pregnancy complications 3. Good health RENAL OUTCOMES LIRAGLUTIDE Basal insulin analogs Glomerular filtration rate business FOLLOW-UP Life Sciences & Biomedicine Mace medicine.drug Kidney disease INSULIN GLARGINE |
| Zdroj: | Diabetes Therapy |
| Popis: | Introduction The associations of chronic kidney disease (CKD) severity, cardiovascular disease (CVD), and insulin with the risks of major adverse cardiovascular events (MACE), mortality, and severe hypoglycemia in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk are not known. This secondary, pooled analysis of data from the DEVOTE trial examined whether baseline glomerular filtration rate (GFR) categories were associated with a higher risk of these outcomes. Methods DEVOTE was a treat-to-target, double-blind trial involving 7637 patients with T2D at high CV risk who were randomized to once-daily treatment with either insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100). Patients with estimated GFR data at baseline (n = 7522) were analyzed following stratification into four GFR categories. Results The risks of MACE, CV death, and all-cause mortality increased with worsening baseline GFR category (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|